Clinical Trials on Metastatic Castration-sensitive Prostate Cancer in Germany
Total 606 results
-
Universität des SaarlandesRecruitingProstate Cancer Metastatic | Advanced Prostate Carcinoma | Castration Resistant Prostatic CancerGermany
-
AstraZenecaRecruitingMetastatic Castration-Sensitive Prostate CancerUnited States, Canada, Spain, United Kingdom, Italy, Australia, Korea, Republic of, Belgium, Germany, Japan, Peru, France, China, India, Taiwan, Thailand, Austria, Brazil, Turkey, Malaysia, Finland, Netherlands, Chile, Hungary, Poland, Sw...
-
Janssen Research & Development, LLCActive, not recruitingMetastatic Castration-sensitive Prostate CancerUnited States, Italy, China, Korea, Republic of, Canada, Australia, United Kingdom, Hungary, France, Taiwan, Thailand, Germany, Malaysia, Denmark, Russian Federation, New Zealand, Ukraine, Bulgaria, Israel, Spain, Turkey, Sweden, Cz... and more
-
BayerCompletedBone Metastatic Castration-resistant Prostate CancerGermany, Netherlands, Denmark
-
Astellas Pharma Europe B.V.Medivation, Inc.CompletedHealthy Subjects | Relative Bioavailability | Castration Resistant Prostate Cancer (CRPC) | MDV3100Germany
-
Astellas Pharma Global Development, Inc.CompletedProstate Cancer | Castration-resistant Prostate Cancer | Metastatic Prostate CancerSpain, Taiwan, France, Algeria, Argentina, Australia, Austria, Brazil, Canada, Colombia, Egypt, Germany, Indonesia, Israel, Italy, Korea, Republic of, Lebanon, Mexico, Netherlands, New Zealand, Oman, Peru, Philippines, Saudi Arabia, Sin... and more
-
Jena University HospitalBayerRecruitingMetastatic Hormone-Sensitive Prostate Cancer (mHSPC)Germany
-
Janssen Research & Development, LLCCompletedMetastatic Breast Cancer | Metastatic Castration-resistant Prostate CancerUnited States, Belgium, Spain, Germany, Sweden, Australia, United Kingdom
-
Janssen-Cilag Ltd.RecruitingMetastatic Hormone-sensitive Prostate CancerFrance, Germany, Spain, Greece, Austria, United Kingdom
-
Astellas Pharma Europe B.V.Medivation, Inc.CompletedMetastatic Castration-Resistant Prostate CancerBelgium, France, Germany, Spain, United Kingdom
-
Technical University of MunichRecruitingCastration-resistant Prostate CancerGermany
-
Janssen Research & Development, LLCRecruitingMetastatic Castrate-sensitive Prostate CancerUnited States, France, Mexico, Germany, Australia, Brazil, Canada, China, Poland
-
SOTIO a.s.CompletedMetastatic Castration-resistant Prostate CancerUnited States, Spain, United Kingdom, Germany, Serbia, Portugal, Lithuania, Slovakia, Hungary, Netherlands, Croatia, France, Czechia, Poland, Austria, Belarus, Belgium, Bulgaria, Denmark, Italy, Latvia, Sweden
-
Modra PharmaceuticalsCompletedCastration-resistant Prostate Cancer | Prostate Cancer MetastaticUnited States, Germany, Hungary, Poland, Russian Federation, Czechia
-
Astellas Pharma Europe Ltd.Medivation, Inc.CompletedMetastatic Castration Resistant Prostate CancerCzechia, Netherlands, Denmark, Italy, Austria, Belgium, Bulgaria, France, Germany, Greece, Hungary, Ireland, Portugal, Slovenia, Spain, United Kingdom
-
BayerOrion Corporation, Orion PharmaCompletedProstate Cancer Non-Metastatic | Castration-ResistantBelgium, France, Poland, Spain, Canada, United States, Estonia, Portugal, Taiwan, Japan, Russian Federation, Finland, Germany, Austria, Czechia, Hungary, Australia, Brazil, South Africa, Latvia, Italy, United Kingdom, Turkey, Serbia, Ro... and more
-
AstraZenecaMerck Sharp & Dohme LLCRecruitingMetastatic Castration-resistant Prostate CancerGermany
-
Astellas Pharma Global Development, Inc.Medivation LLC, a wholly owned subsidiary of Pfizer Inc.Active, not recruitingMetastatic Hormone Sensitive Prostate CancerKorea, Republic of, Japan, United States, Argentina, Australia, Belgium, Canada, Chile, Denmark, Finland, France, Germany, Israel, Italy, Netherlands, New Zealand, Poland, Romania, Russian Federation, Slovakia, Spain, Sweden, Taiwan, United...
-
German Cancer Research CenterUniversity Hospital Freiburg; ABX CRO; Friedrich-Alexander-Universität Erlangen-NürnbergCompletedProstate Cancer | Prostate Cancer Metastatic | High-risk Prostate Cancer | Lymphnode MetastasisAustria, Germany
-
BayerOrion Corporation, Orion PharmaCompletedMetastatic Hormone-sensitive Prostate CancerBelgium, France, Sweden, China, Canada, United States, Spain, Taiwan, Japan, Finland, Korea, Republic of, Australia, Brazil, Czechia, Israel, Italy, Netherlands, Russian Federation, Bulgaria, United Kingdom, Germany, Poland, Mexico
-
AstraZenecaParexelCompletedHealthy Volunteers (Intended Indication: Metastatic Patients With Triple Negative or HR+ Breast Cancer, or Hormone Sensitive Prostate Cancer)Germany
-
Novartis PharmaceuticalsCompletedCastration Resistant Prostate CancerGermany
-
Hinova Pharmaceuticals USA, Inc.Active, not recruitingCastration-resistant Prostate Cancer | Prostate Cancer MetastaticGermany, Spain, Denmark, France, United Kingdom, Russian Federation, Poland, Australia, Italy, Netherlands, United States, Finland, Canada, Austria
-
Merck Sharp & Dohme LLCActive, not recruitingMetastatic Hormone-Sensitive Prostate CancerTaiwan, Poland, United States, Australia, Austria, Brazil, Canada, Chile, China, Colombia, Denmark, Finland, France, Germany, Ireland, Israel, Italy, Japan, Korea, Republic of, Mexico, Netherlands, New Zealand, Peru, Russian Federation, Spai... and more
-
BayerCompletedCastration-Resistant Prostatic CancerGermany
-
Merck Sharp & Dohme LLCRecruitingMetastatic Castration-Resistant Prostate CancerUnited States, Austria, Canada, France, Germany, Ireland, Italy, Mexico, Netherlands, New Zealand, Poland, Russian Federation, Sweden, Taiwan, Turkey, Ukraine, United Kingdom, Spain, Finland, Australia, Denmark
-
BayerActive, not recruitingMetastatic Castration-resistant Prostate CancerUnited States, Austria, Czechia, Israel, Italy, Germany, United Kingdom, France, Mexico, Belgium, Canada, Colombia, Greece, Luxembourg, Netherlands, Spain, Denmark, Sweden, Argentina, Portugal
-
AstraZenecaMerck Sharp & Dohme LLC; Myriad Genetics, Inc.; Foundation Medicine, Inc.CompletedMetastatic Castration-resistant Prostate CancerUnited States, Canada, Denmark, Germany, Italy, Netherlands, Norway, Spain, Argentina, Taiwan, France, Korea, Republic of, Brazil, Japan, Turkey, United Kingdom, Austria, Australia, Israel, Sweden
-
AstraZenecaMerck Sharp & Dohme LLCActive, not recruitingMetastatic Castration-resistant Prostate CancerUnited States, Italy, Spain, Belgium, Canada, France, Korea, Republic of, United Kingdom, Brazil, Czechia, Turkey, Australia, Chile, Germany, Japan, Netherlands, Slovakia
-
Merck Sharp & Dohme LLCOrion Corporation, Orion PharmaRecruitingProstatic Neoplasms | Metastatic Castration-resistant Prostate Cancer (mCRPC)Australia, Germany, United States, Puerto Rico, Israel, Korea, Republic of, Taiwan, China, Costa Rica, Guatemala, Spain, France, Hong Kong, Portugal, Romania, Chile, Czechia, Hungary, Italy, Sweden, Turkey, United Kingdom, Estonia, Ir... and more
-
Astellas Pharma Europe Ltd.Medivation LLC, a wholly owned subsidiary of Pfizer Inc.CompletedMetastatic Castration Resistant Prostate CancerBelgium, France, Spain, Austria, Czechia, Germany, Greece, Italy, Netherlands, Norway, Poland, Russian Federation, Sweden, Switzerland, Turkey, United Kingdom
-
Technische Universität DresdenRecruitingOligometastatic Disease | Prostatic Cancer, Castration-ResistantGermany
-
AstraZenecaActive, not recruitingHormone-Sensitive Prostate CancerUnited States, Belgium, Spain, Canada, Poland, Argentina, India, Taiwan, Thailand, Vietnam, Turkey, Russian Federation, France, Germany, Korea, Republic of, Brazil, Mexico, Peru, Philippines, China, United Kingdom, Hong Kong, Israel, ... and more
-
pharmaand GmbHFoundation MedicineActive, not recruitingMetastatic Castration Resistant Prostate CancerUnited States, Canada, Spain, France, Australia, Ireland, Belgium, Denmark, United Kingdom, Germany, Israel, Italy
-
zr Pharma & GmbHFoundation MedicineCompletedMetastatic Castration Resistant Prostate CancerUnited States, Spain, United Kingdom, France, Australia, Belgium, Denmark, Israel, Germany, Ireland, Canada, Italy
-
PfizerAstellas Pharma Inc; Medivation LLC, a wholly owned subsidiary of Pfizer Inc.CompletedCastration-Resistant Prostate CancerUnited States, Canada, France, Spain, United Kingdom, Australia, Poland, Germany, Austria, Belgium, Netherlands, Italy, Chile, South Africa, Argentina
-
University Hospital TuebingenGerman Cancer Research CenterRecruitingCastration-Resistant Prostatic CancerGermany
-
Astellas Pharma Global Development, Inc.Medivation LLC, a wholly owned subsidiary of Pfizer Inc.CompletedMetastatic Castration-resistant Prostate Cancer (mCRPC)France, Germany, Spain, United States, Argentina, Australia, Belgium, Canada, Chile, Czechia, Finland, Hungary, Israel, Italy, Korea, Republic of, New Zealand, Singapore, Sweden, Taiwan, United Kingdom
-
Association Pour La Recherche des Thérapeutiques...CompletedProstate Cancer MetastaticFrance, Germany
-
Swiss Group for Clinical Cancer ResearchActive, not recruitingMetastatic Breast Cancer | Bone Metastases | Metastatic Prostate CancerSwitzerland, Germany, Austria
-
ExelixisCompletedPain | Prostatic Neoplasms | Prostate Cancer | Castration Resistant Prostate CancerBelgium, France, Italy, Canada, United States, Germany, United Kingdom, Australia, Netherlands, Spain, Austria, Ireland, Puerto Rico, Sweden
-
PfizerAstellas Pharma Inc; Medivation LLC, a wholly owned subsidiary of Pfizer Inc.Active, not recruitingProstate Cancer | Cancer of the Prostate | Nonmetastatic Castration-Resistant Prostate CancerHong Kong, Canada, China, Germany, Spain, Netherlands, United Kingdom, Korea, Republic of, Taiwan, Australia, Denmark, France, United States, Singapore, Poland, Malaysia, Turkey, Belgium, Argentina, Thailand, Slovakia, Brazil, Finland, Ita... and more
-
IpsenTerminatedMetastatic Castrate Resistant Prostate CancerFrance, Spain, Poland, Belgium, Germany, Italy, Denmark, Lithuania, United Kingdom, Czechia, Hungary
-
EMD SeronoCompletedProstate Cancer MetastaticUnited States, Australia, France, Poland, Russian Federation, Spain, Germany, Netherlands, Slovakia, Canada, South Africa, Belgium
-
Movember FoundationKing's College London; Centre hospitalier de l'Université de Montréal (CHUM); University of California, San Francisco and other collaboratorsActive, not recruitingINTense ExeRcise for surviVAL Among Men With Metastatic Prostate Cancer (INTERVAL - GAP4) (INTERVAL)Metastatic Prostate CancerUnited States, Australia, Netherlands, Canada, United Kingdom, Germany, Ireland
-
Novartis PharmaceuticalsCompletedMetastatic Hormone Refractory Prostate CancerUnited States, France, Spain, Belgium, Singapore, Italy, Australia, Germany
-
SanofiCompletedProstate Cancer MetastaticUnited Kingdom, Austria, Belgium, Czechia, France, Germany, Greece, Iceland, Ireland, Italy, Netherlands, Norway, Spain
-
AstraZenecaCompletedNon-Metastatic Prostate CancerCzech Republic, Italy, South Africa, United Kingdom, Germany, Poland, Netherlands, Austria, Belgium, Hungary, Israel, Portugal, Mexico, Spain, Australia, Ireland
-
Bavarian NordicCompletedProstate Cancer MetastaticUnited States, Spain, Germany, Netherlands, Belgium, United Kingdom, Australia, Denmark, France, Canada, Israel, Russian Federation, Puerto Rico, Estonia, Poland, Iceland
-
Ferring PharmaceuticalsCompleted